PA
ITOS

Parallel Advisors’s iTeos Therapeutics ITOS Stock Holding History

Parallel Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$112 – 3574
2024
Q3 		$112 Sell
11
-42
-79% -$641 ﹤0.01% 3331
2024
Q2 		$787 Buy
53
+42
+382% +$602 ﹤0.01% 3012
2024
Q1 		$150 Hold
11
– – ﹤0.01% 3181
2023
Q4 		$120 Buy
+11
New +$109 ﹤0.01% 3214
2023
Q3 		– Sell
-227
Closed -$3K – 3431
2023
Q2 		$3K Buy
227
+63
+38% +$898 ﹤0.01% 2613
2023
Q1 		$2.23K Buy
+164
New +$2.94K ﹤0.01% 2733
2022
Q3 		– Sell
-8
Closed – – 3323
2022
Q2 		$0 Buy
+8
New +$190 ﹤0.01% 3166
2021
Q2 		– Sell
-5
Closed – – 2990
2021
Q1 		$0 Buy
+5
New +$181 ﹤0.01% 2847

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Parallel Advisors's ITOS Position: Q4 2024 in Review

Parallel Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 11 shares — an estimated $112 sold.

Parallel Advisors first reported a position in ITOS in Q1 2021 and held it in 8 quarters. The position peaked at $3K in Q2 2023. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Parallel Advisors reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Parallel Advisors sold 11 iTeos Therapeutics shares in Q4 2024, an estimated $112.
  • Parallel Advisors first reported a position in iTeos Therapeutics in Q1 2021 and held it in 8 quarters.
  • Parallel Advisors's iTeos Therapeutics position peaked at $3K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Parallel Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.